New treatment strategies for primary sclerosing cholangitis

Digestive Diseases

Volumn 29, Issue 1, 2011, Pages 113-116

  Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibiotics; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; AZITHROMYCIN; BUDESONIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; IMMUNOGLOBULIN G4; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; TACROLIMUS; TETRACYCLINE; TRANSFORMING GROWTH FACTOR; URSODEOXYCHOLIC ACID; VANCOMYCIN;

ANTIBODY PRODUCTION; CELL PROLIFERATION; CELL PROTECTION; COLON CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DYSPLASIA; HUMAN; LIVER FIBROSIS; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STELLATE CELL; SURVIVAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHOLANGITIS, SCLEROSING; HUMANS;

EID: 79959500488     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000324145     Document Type: Conference Paper

References (17)

1. Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismuller TJ, Gotthardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns MP, Schrumpf E, Boberg KM, Schreiber S: Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138: 1102-1111.
2. Blanco PG KJ, Petz JL, Zaman MM, Bhaskar K, Cluette-Brown JE, Gutam S, Sheth S, Brown A, Afdhal NH, Lindor KD, Freedman SD: Novel therapeutic approach to primary sclerosing cholangitis. Hepatology 2008; 48 (4 suppl S):598A.
3. Lichtman SN, Sartor RB, Keku J, Schwab JH: Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98:414-423. (Pubitemid 20037925)
4. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD: A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:2338-2342.
5. Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Karkkainen P: Metronidazole and ursode-oxycholic acid for primary sclerosing chol-angitis: a randomized placebo-controlled trial. Hepatology 2004; 40:1379-1386. (Pubitemid 39657012)
6. Elfaki DA, Lindor KD: Antibiotics for the treatment of primary sclerosing cholangitis. Am J Ther 2009, E-pub ahead of print.
7. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD: Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005; 100:308-312. (Pubitemid 40314514)
8. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN: Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007; 27:451-453. (Pubitemid 46534566)
9. Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD: Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:2333-2337.
10. Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90:455-459.
11. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD: Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101:2070-2075. (Pubitemid 44337633)
12. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group. N Engl J Med 1997; 336:691-695.
13. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121:900-907. (Pubitemid 32959399)
14. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95. (Pubitemid 32096335)
15. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124:889-893. (Pubitemid 36389790)
16. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsoy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzen H, Ung KA, Eriksson A, Loof L, Prytz H, Marschall HU, Broome U: Highdose ursodeoxycholic acid in primary scle-rosing chola ngit is: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129:1464-1472. (Pubitemid 41597389)
17. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814.